drugset / Trial / NCT03859414

PK of BDP/FF/GB Single-inhaler Triple Therapy in Japanese vs. Caucasians

NCT03859414

Phase 1 Completed 32 enrolled Chiesi Farmaceutici S.p.A.
RandomizedCrossoverQuadruple-blindOther

Summary

The purpose of conducting this study is to obtain PK data of Beclometasone Dipropionate (BDP)/Beclometasone-17-MonoPropionate (B17MP), Formoterol Fumarate (FF) and Glycopyrronium Bromide (GB) after inhalation of CHF 5993 in Japanese as well as Caucasian healthy subjects under the same setting.

Timeline

Start
2019-03-18
Primary completion
2019-07-24
Completion
2019-07-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Formoterol Other / unclassified 12 ug Inhaled
Subject Formoterol Other / unclassified 48 ug Inhaled
Subject Glycopyrronium Unknown 25 ug Inhaled
Subject Glycopyrronium Unknown 100 ug Inhaled
Subject beclomethasone dipropionate Other / unclassified 200 ug Inhaled
Subject beclomethasone dipropionate Other / unclassified 400 ug Inhaled
Subject beclomethasone dipropionate Other / unclassified 800 ug Inhaled